Please login to the form below
Adderall XR
This page shows the latest Adderall XR news and features for those working in and with pharma, biotech and healthcare.
Shire offloads oncology unit to Servier for $2.4bn
The neuroscience arm includes Shire’s attention-deficit hyperactivity drugs such as Adderall XR (mixed amphetamine salts) and brought in $2.66bn in sales last year.
Latest news
-
Shire claims FDA approval for slow-cooked ADHD drug
modest $288m by 2020, mainly because of anticipated payer resistance in the US as the new drug has the same ingredients as Adderall XR. ... Either way the new drug is a boost to Shire's ADHD franchise now that Adderall XR and Intuniv (guanfacine) have
-
Shire pitching at adult ADHD product launch in 2017
Adults already receive treatment for ADHD off-label using drugs such as Adderall and Adderall XR - both also based on mixed amphetamine salts - but it is though that a sizeable proportion
-
Shire reaches $56.5m US marketing malpractice settlement
Justice Department agreement covers activities for drugs including Adderall. Irish biopharma company Shire has agreed to pay a multi-million dollar fine to the US Justice Department to settle allegations that ... The allegations included its attention
-
Pay-for-delay deals lead to inflated drug prices says study
Based on analysis of delayed market entry of generic Adderall XR in US. ... The study models a deal that delayed generic competition to Shire's attention-deficit hyperactivity disorder (ADHD) drug Adderall XR in the US and concluded that percentage price
-
Shire misses Q1 targets as Replagal sales fall
Despite these setbacks, Shire's core attention-deficit hyperactivity disorder (ADHD) franchise delivered the goods, with Vyvanse (lisdexamfetamine) and Adderall XR (mixed amphetamine salts) doing better than expected. ... Vyvanse grew 15 per cent to
More from news
Approximately 3 fully matching, plus 68 partially matching documents found.
Latest appointments
-
Shire elects new chair
During that time Shire has grown substantially, although has struggled in recent years with generic competition for big-selling attention deficit-hyperactivity disorder (ADHD) drug Adderall XR and plans to downsize
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- First patients dosed with COVID-19 vaccine from SpyBiotech and Serum Institute of India
- Gilead agrees $21bn buyout of Immunomedics
- FDA approves Roche’s Actemra COVID-19 trial
- First patients dosed with COVID-19 vaccine from SpyBiotech and Serum Institute of India
- Positive COPD data for Synairgen's SNG001 supports COVID-19 programme
- Roche’s Ocrevus boasts positive long-term data in MS
PMHub
Aptus Health
Aptus Health is dedicated to advancing health engagement. The company offers end-to-end digital health engagement solutions spanning all areas of...
Latest intelligence
- 7 important considerations for creating an inclusive clinical trial website
- You might have noticed that all of us here at COUCH Health are big advocates for taking action to improve diversity and inclusion in the world of clinical research. ‘Taking...
- Route 66: can remote working put two-thirds of us back on the road to engaged employment?
- Pre-pandemic, 66% of the world’s workforce weren’t engaged in their jobs – Chris Ross examines how the rush to remote working has impacted employee engagement...
- Demonstrating the value of HCP self-serve portals
- Develop the art of setting KPIs and metrics aligned to your specific objectives, target personas, key educational messages, content, website features and journeys....
Quick links
Infographics
